

NOTICE TO THE BAR

REVISIONS TO CIVIL CASE INFORMATION STATEMENT SIDE 2

Effective immediately, Side 2 of the Civil Case Information Statement (Civil CIS) is revised to reflect the addition of several new case types, as follows:

- The addition of case type 620 for cases filed under the New Jersey False Claims Act, N.J.S.A. 2A:32C-1 et seq.
- The addition of case type 279 for the Gadolinium-Based Contrast Agent litigation, pursuant to the Supreme Court's April 8, 2008 Order designating the litigation as a mass tort.
- The addition of case type 280 for the Zelnorm litigation, pursuant to the Supreme Court's September 8, 2008 Order centralizing the management of the litigation but not designating it as a mass tort.
- The addition of case type 281 for the Bristol-Myers Squibb Environmental litigation, pursuant to the Supreme Court's October 6, 2008 Order designating it as a mass tort.
- The addition of case type 282 for the Fosamax litigation, pursuant to the Supreme Court's October 6, 2008 Order designating it as a mass tort.
- The addition of case type 283 for the Digitek litigation, pursuant to the Supreme Court's January 5, 2009 Order designating it as a mass tort.
- The addition of case type 284 for the NuvaRing litigation, pursuant to the Supreme Court's March 10, 2009 Order designating it as a mass tort.

Questions concerning these changes to Side 2 of the Civil CIS may be directed to Michelle V. Perone, Esq., Chief, Civil Court Programs, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone 609-984-5431; e-mail address: michelle.perone@judiciary.state.nj.us.

/s/ Glenn A. Grant

Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: March 17, 2009



CIVIL CASE INFORMATION STATEMENT (CIS)

Use for initial pleadings (not motions) under *Rule 4:5-1*

CASE TYPES (Choose one and enter number of case type in appropriate space on the reverse side.)

Track I — 150 days' discovery

- 151 NAME CHANGE
- 175 FORFEITURE
- 302 TENANCY
- 399 REAL PROPERTY (other than Tenancy, Contract, Condemnation, Complex Commercial or Construction)
- 502 BOOK ACCOUNT (debt collection matters only)
- 505 OTHER INSURANCE CLAIM (INCLUDING DECLARATORY JUDGMENT ACTIONS)
- 506 PIP COVERAGE
- 510 UM or UIM CLAIM
- 511 ACTION ON NEGOTIABLE INSTRUMENT
- 512 LEMON LAW
- 801 SUMMARY ACTION
- 802 OPEN PUBLIC RECORDS ACT (SUMMARY ACTION)
- 999 OTHER (Briefly describe nature of action)

Track II — 300 days' discovery

- 305 CONSTRUCTION
- 509 EMPLOYMENT (other than CEPA or LAD)
- 599 CONTRACT/COMMERCIAL TRANSACTION
- 603 AUTO NEGLIGENCE – PERSONAL INJURY
- 605 PERSONAL INJURY
- 610 AUTO NEGLIGENCE – PROPERTY DAMAGE
- 699 TORT – OTHER

Track III — 450 days' discovery

- 005 CIVIL RIGHTS
- 301 CONDEMNATION
- 602 ASSAULT AND BATTERY
- 604 MEDICAL MALPRACTICE
- 606 PRODUCT LIABILITY
- 607 PROFESSIONAL MALPRACTICE
- 608 TOXIC TORT
- 609 DEFAMATION
- 616 WHISTLEBLOWER / CONSCIENTIOUS EMPLOYEE PROTECTION ACT (CEPA) CASES
- 617 INVERSE CONDEMNATION
- 618 LAW AGAINST DISCRIMINATION (LAD) CASES
- 620 FALSE CLAIMS ACT

Track IV — Active Case Management by Individual Judge / 450 days' discovery

- 156 ENVIRONMENTAL/ENVIRONMENTAL COVERAGE LITIGATION
- 280 ZELNORM
- 303 MT. LAUREL
- 508 COMPLEX COMMERCIAL
- 513 COMPLEX CONSTRUCTION
- 514 INSURANCE FRAUD
- 701 ACTIONS IN LIEU OF PREROGATIVE WRITS

Mass Tort (Track IV)

- | | |
|---------------------------------------|--|
| 248 CIBA GEIGY | 278 ZOMETA/AREIDIA |
| 266 HORMONE REPLACEMENT THERAPY (HRT) | 279 GADOLINIUM |
| 271 ACCUTANE | 281 BRISTOL-MYERS SQUIBB ENVIRONMENTAL |
| 272 BEXTRA/CELEBREX | 282 FOSAMAX |
| 274 RISPERDAL/SEROQUEL/ZYPREXA | 283 DIGITEK |
| 275 ORTHO EVRA | 284 NUVARING |
| 276 DEPO-PROVERA | 601 ASBESTOS |
| 277 MAHWAH TOXIC DUMP SITE | 619 VIOXX |

If you believe this case requires a track other than that provided above, please indicate the reason on Side 1, in the space under "Case Characteristics."

Please check off each applicable category:

Verbal Threshold

Putative Class Action

Title 59